Characterization of a Neuraminidase-Deficient Influenza A Virus as a Potential Gene Delivery Vector and a Live Vaccine
- 15 March 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (6) , 3083-3088
- https://doi.org/10.1128/jvi.78.6.3083-3088.2004
Abstract
We recently identified a packaging signal in the neuraminidase (NA) viral RNA (vRNA) segment of an influenza A virus, allowing us to produce a mutant virus [GFP(NA)-Flu] that lacks most of the NA open reading frame but contains instead the gene encoding green fluorescent protein (GFP). To exploit the expanding knowledge of vRNA packaging signals to establish influenza virus vectors for the expression of foreign genes, we studied the replicative properties of this virus in cell culture and mice. Compared to wild-type virus, GFP(NA)-Flu was highly attenuated in normal cultured cells but was able to grow to a titer of >10 6 PFU/ml in a mutant cell line expressing reduced levels of sialic acid on the cell surface. GFP expression from this virus was stable even after five passages in the latter cells. In intranasally infected mice, GFP was detected in the epithelial cells of nasal mucosa, bronchioles, and alveoli for up to 4 days postinfection. We attribute the attenuated growth of GFP(NA)-Flu to virion aggregation at the surface of bronchiolar epithelia. In studies to test the potential of this mutant as a live attenuated influenza vaccine, all mice vaccinated with ≥10 5 PFU of GFP(NA)-Flu survived when challenged with lethal doses of the parent virus. These results suggest that influenza virus could be a useful vector for expressing foreign genes and that a sialidase-deficient virus may offer an alternative to the live influenza vaccines recently approved for human use.Keywords
This publication has 58 references indexed in Scilit:
- Development of a DIVA (Differentiating Infected from Vaccinated Animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenzaAvian Pathology, 2003
- Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genesCancer Gene Therapy, 2002
- Accumulation of Defective Neuraminidase (NA) Genes by Influenza A Viruses in the Presence of NA Inhibitors as a Marker of Reduced Dependence on NAThe Journal of Infectious Diseases, 2002
- Immunogenicity and Protective Efficacy of Replication-Incompetent Influenza Virus-Like ParticlesJournal of Virology, 2002
- The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigenExpert Opinion on Biological Therapy, 2002
- Detection of Amantadine-Resistant Influenza A Virus Strains in Nursing Homes by PCR-Restriction Fragment Length Polymorphism Analysis with Nasopharyngeal SwabsJournal of Clinical Microbiology, 2002
- Adaptation of Influenza A Viruses to Cells Expressing Low Levels of Sialic Acid Leads to Loss of Neuraminidase ActivityJournal of Virology, 2001
- Efficient Expression of the Tumor-Associated Antigen MAGE-3 in Human Dendritic Cells, Using an Avian Influenza Virus VectorHuman Gene Therapy, 2000
- Chimeric Influenza Virus Replicating Predominantly in the Murine Upper Respiratory Tract Induces Local Immune Responses against Human Immunodeficiency Virus Type 1 in the Genital TractThe Journal of Infectious Diseases, 1998
- Mutational analysis of influenza virus promoter elements in vivoJournal of General Virology, 1995